<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771728</url>
  </required_header>
  <id_info>
    <org_study_id>PUshenzhenH2020-0310</org_study_id>
    <nct_id>NCT04771728</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized Controlled Study of the Probiotics as Adjuvant Treatment for Bacterial Vaginosis</brief_title>
  <official_title>Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Shenzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BGI, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Shenzhen Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are trying to determine if oral Probiotics(Umeta-mimi,30 days) with&#xD;
      Metronidazole vaginal suppositories (7 days) is better than using Metronidazole vaginal&#xD;
      suppositories(7 days) only in preventing the recurrence of bacterial vaginosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies have shown that oral Probiotics(Umeta-mimi) can significantly promote the recovery of&#xD;
      vaginal flora mainly because intestinal microbiota can migrate and affect vaginal&#xD;
      microecology. This project aims to evaluate the efficacy of oral Probiotics(Umeta-mimi,30&#xD;
      days) with Metronidazole vaginal suppositories(7 days) in the treatment of bacterial&#xD;
      vaginosis (BV) and to explore the correlation between vaginal flora and fecal flora by&#xD;
      detecting the metagenomics of vaginal secretions and intestinal feces at the time of baseline&#xD;
      phase,14 days after treatment， the first month after treatment, 5-7 days after third&#xD;
      menstruation after treatment and 5-7 days after sixth menstruation after treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cure rate of BV</measure>
    <time_frame>14 days after treatment</time_frame>
    <description>Assessments with different Units of Measure:clinical symptoms such as itching or burning; &quot;fishy&quot; smell; homogeneous thin vaginal discharge;Nugent score; pH&gt;4.5; clue cell.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV</measure>
    <time_frame>The first month after treatment</time_frame>
    <description>Nugent score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV</measure>
    <time_frame>5-7 days after third menstruation after treatment</time_frame>
    <description>Nugent score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of BV</measure>
    <time_frame>5-7 days after sixth menstruation after treatment</time_frame>
    <description>Nugent score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <arm_group>
    <arm_group_label>Metronidazole vaginal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole vagianl and Probiotics(Umeta-mimi)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metronidazole:Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) Probiotics:Oral Umeta-mimi( 5×109cfu per day,30 days）</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole vaginal suppositories</intervention_name>
    <description>Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days )</description>
    <arm_group_label>Metronidazole vaginal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole vaginal suppositories and Probiotics(Umeta-mimi)</intervention_name>
    <description>Metronidazole vaginal suppositories (200 mg,2 capsules per day,7 days ) and Oral pobiotics(Umeta-mimi,5×109cfu per day,30 days）</description>
    <arm_group_label>Metronidazole vagianl and Probiotics(Umeta-mimi)</arm_group_label>
    <other_name>Metronidazole vaginal suppositories adn Probiotics(Umeta-mimi）</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18 to 55 years old, with history of sexual activity,&#xD;
&#xD;
          2. Amsel criterion for diagnosing BV&#xD;
&#xD;
          3. Sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of systemic organic diseases or psychiatric diseases&#xD;
&#xD;
          2. Planning for or during pregnancy, lactation, menstruation&#xD;
&#xD;
          3. within 5 days of onset of the disease, any antibiotics has been used&#xD;
&#xD;
          4. Long-term use of contraceptives or immunosuppressant&#xD;
&#xD;
          5. Anaphylactic constitution or allergic to known ingredients of research drugs&#xD;
&#xD;
          6. No same fixed partner (RSP) before and after treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruifang Wu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Dept of Obstetrics and Gynecology,Peking University Shenzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shangrong Fan, M.D.</last_name>
    <phone>86-755-83923333</phone>
    <phone_ext>5505</phone_ext>
    <email>fanshangrong@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yiheng Liang, M.D.</last_name>
    <phone>86-755-83923333</phone>
    <phone_ext>5505</phone_ext>
    <email>13510331823@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Shenzhen Hosptal</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518036</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiheng Liang, M.D.</last_name>
      <phone>8675583923333</phone>
      <phone_ext>5505</phone_ext>
      <email>13510331823@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University Shenzhen Hospital</investigator_affiliation>
    <investigator_full_name>Shangrong Fan</investigator_full_name>
    <investigator_title>Professor of Dept of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginosis, Bacterial</mesh_term>
    <mesh_term>Vaginal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

